Allergy medication safe for atrial fibrillation (AF) is an important consideration for the estimated 1.4 million people in the UK living with this common heart rhythm disorder. Managing hay fever, allergic rhinitis, or urticaria alongside AF requires careful thought, as certain allergy treatments — particularly decongestants and first-generation antihistamines — can trigger arrhythmias, raise heart rate, or interact with anticoagulants. Fortunately, several effective options exist that carry a low cardiac risk profile. This article outlines which allergy medicines are generally considered safer for people with AF, which to avoid, and when to seek professional advice.

Managing Allergies When You Have Atrial Fibrillation

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the UK, affecting an estimated 1.4 million people (British Heart Foundation). Managing everyday conditions such as hay fever, allergic rhinitis, or urticaria becomes more complex when you have AF, because certain allergy medications can interact with heart rhythm or alter blood pressure. Decongestants and some herbal remedies carry the most significant interaction risks; most standard H1 antihistamines have minimal interaction with anticoagulants such as warfarin or direct oral anticoagulants (DOACs), though this should always be confirmed with your pharmacist or GP.

The primary concern for people with AF is avoiding substances that may trigger or worsen arrhythmias, raise heart rate, or increase the risk of adverse cardiovascular events. Some allergy treatments — particularly those containing decongestants or certain older antihistamines — carry these risks and should be used with caution or avoided altogether.

It is important to note that allergy symptoms themselves, if severe, can place physiological stress on the body and potentially influence heart rate. Effective, safe allergy management is therefore genuinely important for people living with AF — not merely a matter of comfort. Working with your GP, cardiologist, or pharmacist to identify appropriate treatments is strongly recommended before starting any new allergy medication.

Which Antihistamines Are Considered Safer With AF

Second-generation, non-sedating antihistamines are generally the preferred choice for people with AF who require allergy relief. These medicines work by selectively blocking peripheral H1 histamine receptors, reducing symptoms such as sneezing, itching, and runny nose, while having minimal sedative or cardiovascular effects compared to older alternatives (NICE CKS: Allergic rhinitis).

The following second-generation antihistamines are widely used in the UK and are broadly considered safer options for people with cardiac conditions, including AF:

• Cetirizine (e.g., Zirtek) — available over the counter; generally well tolerated with a low cardiac risk profile. Note that cetirizine may cause drowsiness in some people; exercise caution when driving or operating machinery.

• Loratadine (e.g., Clarityn) — non-sedating; considered one of the most cardiac-friendly antihistamines available.

• Fexofenadine (e.g., Telfast) — non-sedating and does not significantly affect cardiac conduction at standard doses.

• Acrivastine (e.g., Benadryl Allergy Relief) — shorter-acting; generally considered low risk, though less commonly recommended for long-term use.

Loratadine and fexofenadine are generally preferred in people with cardiac conditions because, at standard doses, they have minimal effect on the QT interval — the measure of electrical activity in the heart that, when prolonged, can increase the risk of dangerous arrhythmias (BNF; NICE CKS: Allergic rhinitis). Other non-sedating prescription options, such as desloratadine and bilastine, may also be considered where appropriate; discuss these with your GP.

Important: Some brand variants carry the same name but contain added decongestants (for example, products labelled 'Plus' or 'Max Strength' may include pseudoephedrine or phenylephrine). Always check the full list of active ingredients on the packaging, and seek pharmacist advice if you are unsure. Never assume a familiar brand name is safe without checking its formulation.

Allergy Medications to Use With Caution or Avoid in AF

First-generation antihistamines — such as chlorphenamine (Piriton) and promethazine — are generally best avoided in people with AF. These older antihistamines cross the blood-brain barrier more readily, causing sedation, and they also have anticholinergic properties that can affect heart rate and cardiac conduction (BNF). Their anticholinergic burden is of particular concern in older adults, where it may also increase the risk of falls and confusion. Promethazine carries a recognised risk of QT interval prolongation; chlorphenamine has also been associated with cardiac conduction effects, though the evidence is less robust — caution is nonetheless advised (BNF; SmPC).

Hydroxyzine (e.g., Atarax, Ucerax) warrants specific mention. The MHRA issued a Drug Safety Update in 2015 confirming that hydroxyzine carries a risk of QT interval prolongation and Torsade de Pointes (a potentially life-threatening arrhythmia). People with risk factors for QT prolongation — including those with AF or other arrhythmias — should avoid hydroxyzine. If it is considered essential, it should be used at the lowest effective dose for the shortest possible duration, under medical supervision.

Some antihistamines, including diphenhydramine (found in some sleep aids and combination cold remedies), carry similar anticholinergic and cardiac concerns and are generally inappropriate for people with AF.

Combination allergy products deserve particular scrutiny. Many over-the-counter cold and allergy remedies combine an antihistamine with a decongestant such as pseudoephedrine or phenylephrine. These combinations — for example, products labelled 'non-drowsy' or 'day and night' formulations — can be especially problematic for people with AF and should generally be avoided unless specifically approved by a healthcare professional.

Topical nasal corticosteroid sprays (such as fluticasone or beclometasone) and antihistamine eye drops are generally considered low-risk options for localised allergy symptoms, as systemic absorption is minimal. These may be suitable alternatives for some patients and are recommended as first-line options for allergic rhinitis by NICE.

How Decongestants and Other Allergy Treatments Affect Heart Rhythm

Decongestants are among the most significant allergy-related concerns for people with AF. Medicines such as pseudoephedrine and phenylephrine — found in many over-the-counter cold and sinus products — work as sympathomimetic agents, meaning they stimulate the sympathetic nervous system. This can cause:

• Increased heart rate (tachycardia)

• Elevated blood pressure

• Potential triggering or worsening of arrhythmias, including AF

For people already prone to irregular heart rhythms, these effects can be clinically significant. The NHS advises that people with heart disease or arrhythmias should seek pharmacist or GP advice before using any product containing pseudoephedrine or phenylephrine (NHS Medicines A–Z). People with AF are generally advised to avoid oral decongestants; if you are unsure whether a product contains a decongestant, ask your pharmacist before purchasing.

Topical nasal decongestants — such as xylometazoline or oxymetazoline nasal sprays — are sometimes considered less risky than oral forms because systemic absorption is lower. However, they can still raise blood pressure and heart rate, particularly with prolonged use. If used at all in people with cardiovascular disease, they should be used with caution and for no more than seven days, in line with product SmPC guidance.

Leukotriene receptor antagonists such as montelukast (used in allergic rhinitis and asthma) are not known to carry significant cardiac risks. However, the MHRA and NHS have issued warnings regarding neuropsychiatric adverse effects associated with montelukast, including mood changes, sleep disturbances, and, rarely, suicidal thoughts. Patients and carers should be made aware of these risks. Montelukast is prescription-only in the UK and should be managed by a GP.

Allergen immunotherapy (desensitisation) is another option for some patients with severe allergic rhinitis, but this is a specialist treatment. People with significant cardiovascular disease or those taking beta-blockers require careful assessment before starting immunotherapy, as beta-blockers can complicate the management of anaphylaxis — a rare but serious risk of this treatment (BSACI guideline: Allergen immunotherapy).

Natural or herbal remedies marketed for allergy relief — such as butterbur or certain herbal teas — have variable and often poorly characterised safety profiles. Importantly, some herbal products (for example, St John's wort and ginkgo) can interact with anticoagulants such as warfarin and DOACs, potentially affecting bleeding risk (Specialist Pharmacy Service). These products should always be discussed with a healthcare professional before use.

Speaking to Your GP or Pharmacist About Allergy Relief With AF

Before starting any new allergy medication — whether prescription or over the counter — people with AF should consult their GP or a qualified pharmacist. This is particularly important because:

• Drug interactions with anticoagulants (warfarin, apixaban, rivaroxaban, edoxaban, dabigatran) or rate-control medicines (such as beta-blockers or digoxin) may occur, particularly with decongestants and herbal products. Most standard H1 antihistamines have minimal impact on INR or DOAC levels, but some OTC cold remedies and herbal products (e.g., St John's wort, ginkgo) can interact with anticoagulants and should be used with caution.

• Individual risk factors such as heart failure, hypertension, or kidney impairment may influence which treatments are appropriate.

• Combination products may contain hidden decongestants; always check the active ingredients.

Your pharmacist is an excellent first point of contact for over-the-counter allergy queries. UK pharmacists are trained to screen for contraindications and interactions and can advise on the safest available options without the need for a GP appointment. In England, the NHS Community Pharmacist Consultation Service (CPCS) provides access to pharmacist-led consultations for minor illness and urgent medicine supply. The New Medicine Service (NMS) is available in England for patients newly prescribed certain medicines and may be relevant if your GP starts you on a new allergy treatment.

If you experience any of the following after taking an allergy medication, seek prompt medical advice:

• Palpitations or a noticeably irregular heartbeat

• Chest tightness or discomfort

• Dizziness or fainting

• Significant increase in heart rate

These symptoms may indicate that the medication is affecting your heart rhythm and should be assessed promptly. In an emergency, call 999 or attend your nearest A&E department.

If you suspect that an allergy medication has caused an unwanted side effect, you can report this directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps the MHRA monitor the safety of medicines in the UK.

NICE and NHS Guidance on Antihistamine Use in Cardiac Conditions

NICE guidance on allergic rhinitis (NICE CKS: Allergic rhinitis) recommends intranasal corticosteroids and second-generation, non-sedating antihistamines as first-line treatments for most adults, citing their favourable tolerability profile. While NICE CKS does not specifically address AF in the context of antihistamine prescribing, the broader principle of preferring agents with minimal cardiovascular effects is well established in UK clinical practice.

The NHS advises that people with heart conditions should always read the label of any over-the-counter medicine carefully and seek pharmacist advice if they are unsure. The NHS also highlights that combination cold and flu remedies frequently contain decongestants and should be avoided by those with heart rhythm disorders (NHS Medicines A–Z: Pseudoephedrine; Phenylephrine).

The MHRA regulates the safety of medicines in the UK and has issued communications regarding the cardiovascular risks of sympathomimetic decongestants, as well as specific Drug Safety Updates on hydroxyzine (QT prolongation, 2015) and montelukast (neuropsychiatric effects). Patients and clinicians are encouraged to report suspected adverse drug reactions — including cardiac effects — via the Yellow Card scheme (yellowcard.mhra.gov.uk).

For people with AF managed under a cardiologist or specialist AF clinic, it is advisable to mention any new allergy treatments at your next review appointment. Integrated care between primary and secondary care teams ensures that allergy management does not inadvertently compromise cardiac stability. Ultimately, safe allergy relief is achievable for most people with AF — it simply requires informed, personalised guidance from a qualified healthcare professional.

Frequently Asked Questions